Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Nonalcoholic steatohepatitis

B A Neuschwander-Tetri1, B R Bacon

  • 1Department of Internal Medicine, Saint Louis University School of Medicine, Missouri 63110, USA.

The Medical Clinics of North America
|September 1, 1996
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Randomised clinical study: GR-MD-02, a galectin-3 inhibitor, vs. placebo in patients having non-alcoholic steatohepatitis with advanced fibrosis.

Alimentary pharmacology & therapeutics·2016
Same author

Real-world effectiveness for 12 weeks of ledipasvir-sofosbuvir for genotype 1 hepatitis C: the Trio Health study.

Journal of viral hepatitis·2016
Same author

Disparate access to treatment regimens in chronic hepatitis C patients: data from the TRIO network.

Journal of viral hepatitis·2016
Same author

Vitamin E and changes in serum alanine aminotransferase levels in patients with non-alcoholic steatohepatitis.

Alimentary pharmacology & therapeutics·2013
Same author

Adherence to assigned dosing regimen and sustained virological response among chronic hepatitis C genotype 1 patients treated with boceprevir plus peginterferon alfa-2b/ribavirin.

Alimentary pharmacology & therapeutics·2013
Same author

Meta-analysis: re-treatment of genotype I hepatitis C nonresponders and relapsers after failing interferon and ribavirin combination therapy.

Alimentary pharmacology & therapeutics·2010
Same journal

Care Transitions Continue to Evolve.

The Medical clinics of North America·2026
Same journal

Navigating the Gaps: A Comprehensive Overview of Care Transitions Across the Continuum.

The Medical clinics of North America·2026
Same journal

Care Transitions and Value-Based Payment Models in the United States.

The Medical clinics of North America·2026
Same journal

Technology and Innovation in Care Transitions: Imagining the Future of Postdischarge Care.

The Medical clinics of North America·2026
Same journal

Primary Care, Specialists, and Hospitals: Bridging the Gaps in Communication and Coordination.

The Medical clinics of North America·2026
Same journal

Social Determinants of Health: Unique Considerations in Transitions of Care.

The Medical clinics of North America·2026
See all related articles

Non-alcoholic steatohepatitis (NASH) is a chronic liver disease that can progress to cirrhosis. Early recognition via liver biopsy is crucial, especially in patients without traditional risk factors like obesity or diabetes.

Area of Science:

  • Hepatology
  • Gastroenterology
  • Internal Medicine

Background:

  • Non-alcoholic steatohepatitis (NASH) is a chronic liver disease.
  • NASH can mimic alcoholic hepatitis histologically.
  • It may progress to fibrosis, cirrhosis, and end-stage liver disease.

Purpose of the Study:

  • To highlight the importance of recognizing NASH.
  • To emphasize the role of liver biopsy in unexplained liver abnormalities.
  • To discuss current treatment and future diagnostic possibilities.

Main Methods:

  • Review of existing literature on NASH.
  • Analysis of patient demographics and risk factors.
  • Discussion of diagnostic criteria and treatment approaches.

Related Experiment Videos

Main Results:

  • NASH affects a significant proportion of patients without traditional risk factors (diabetes, obesity).
  • Liver biopsy is essential for diagnosing NASH in cases of unexplained liver biochemical abnormalities.
  • Weight reduction is the primary treatment for obese patients; others require observation.

Conclusions:

  • NASH recognition is critical due to its progressive nature.
  • Liver biopsy remains a key diagnostic tool.
  • Further research into NASH pathophysiology may yield targeted therapies.